A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 14012 participants.

Also called NCT05739383

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 14,012 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05739383
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Greece, Hong Kong SAR China, Hungary, India, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Philippines, Poland, Portugal, Puerto Rico, Romania, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05739383. Randomized; quadruple masking; primary purpose prevention. Start 2023-03-09 (actual); primary completion 2029-04-16 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Condition
Primary Prevention of Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Intervention (Drug)
Placebo in 1.5ml
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05739383
Content hash
e046bd998abb2e4c988c5ea3119d068ed32fdeed33305554651fb1334c430604